Comparative Pharmacology
Head-to-head clinical analysis: BRETYLIUM TOSYLATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus SOTALOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRETYLIUM TOSYLATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus SOTALOL HYDROCHLORIDE.
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs SOTALOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bretylium tosylate inhibits norepinephrine release from adrenergic nerve terminals by blocking neuronal reuptake and causing initial norepinephrine release followed by depletion. It also exhibits class III antiarrhythmic activity by prolonging the action potential duration and refractory period in cardiac Purkinje fibers and ventricular muscle.
Sotalol is a non-selective beta-adrenergic receptor antagonist (beta-blocker) with additional class III antiarrhythmic activity (prolongation of cardiac action potential duration via blockade of potassium channels). It decreases heart rate, myocardial contractility, and AV conduction velocity, and increases ventricular refractoriness.
For ventricular tachycardia/fibrillation: 5 mg/kg IV over 8-10 minutes, then 5-10 mg/kg IV q6-8h. For continuous infusion: 1-2 mg/min IV.
Initial: 80 mg orally twice daily; may increase every 3 days to 160-320 mg/day, maximum 640 mg/day (for life-threatening arrhythmias). Also available as 80 mg intravenous over 20 minutes (1.5 mg/kg) for acute management.
None Documented
None Documented
Terminal half-life: 7-11 hours (normal renal function); prolonged in renal impairment (up to 16-32 hours in anuria)
Terminal elimination half-life: 10-20 hours in normal renal function; prolonged in renal impairment (up to 40 hours), requiring dose adjustment.
Renal: >80% unchanged; biliary/fecal: minimal (<5%)
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <20%.
Category C
Category A/B
Antiarrhythmic (Class III)
Antiarrhythmic (Class III)